title: Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.
abstract: Influenza viruses collected from regions of Asia, Africa and Oceania between 2009 and 2012 were tested for their susceptibility to two new neuraminidase inhibitors, peramivir and laninamivir. All viruses tested had normal laninamivir inhibition. However, 3·2% (19/599) of A(H1N1)pdm09 viruses had highly reduced peramivir inhibition (due to H275Y NA mutation) and <1% (6/1238) of influenza B viruses had reduced or highly reduced peramivir inhibition, with single occurrence of variants containing I221T, A245T, K360E, A395E, D432G and a combined G145R+Y142H mutation. These data demonstrate that despite an increase in H275Y variants in 2011, there was no marked change in the frequency of peramivir- or laninamivir-resistant variants following the market release of the drugs in Japan in 2010.
authors.forename: Sook-Kwan
authors.initials: SK
authors.lastname: Leang
authors.forename: Simon
authors.initials: S
authors.lastname: Kwok
authors.forename: Sheena G
authors.initials: SG
authors.lastname: Sullivan
authors.forename: Sebastian
authors.initials: S
authors.lastname: Maurer-Stroh
authors.forename: Anne
authors.initials: A
authors.lastname: Kelso
authors.forename: Ian G
authors.initials: IG
authors.lastname: Barr
authors.forename: Aeron C
authors.initials: AC
authors.lastname: Hurt
mesh_terms: D000146:Acids, Carbocyclic; D000349:Africa; D000998:Antiviral Agents / Q000494:pharmacology*; D001208:Asia; D003517:Cyclopentanes / Q000494:pharmacology*; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects* / Q000302:isolation & purification; D009981:Influenza B virus / Q000187:drug effects* / Q000302:isolation & purification; D007251:Influenza, Human / Q000821:virology; D007564:Japan; D008826:Microbial Sensitivity Tests; D020125:Mutation, Missense; D009439:Neuraminidase / Q000037:antagonists & inhibitors / Q000235:genetics; D044349:Oceania; D011714:Pyrans; D012794:Sialic Acids; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D053243:Zanamivir / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D014764:Viral Proteins; C546918:laninamivir; C487630:NA protein, influenza A virus; C541223:NA protein, influenza B virus; D009439:Neuraminidase; D053243:Zanamivir; C414210:peramivir
references.citation: Antiviral Res. 2013 Sep;99(3):261-9
references.pmid: 23791870
references.citation: Influenza Other Respir Viruses. 2013 Nov;7(6):1390-9
references.pmid: 23745712
references.citation: Emerg Infect Dis. 2011 Nov;17(11):2043-6
references.pmid: 22099093
references.citation: Antiviral Res. 2013 Feb;97(2):206-10
references.pmid: 23274624
references.citation: Antiviral Res. 2013 Mar;97(3):240-4
references.pmid: 23267831
references.citation: N Engl J Med. 2009 Dec 3;361(23):2204-7
references.pmid: 19884645
references.citation: Expert Rev Anti Infect Ther. 2012 Feb;10(2):123-43
references.pmid: 22339187
references.citation: Wkly Epidemiol Rec. 2012 Sep 28;87(39):369-74
references.pmid: 23061103
references.citation: N Engl J Med. 2011 Dec 29;365(26):2541-2
references.pmid: 22204735
references.citation: Methods Mol Biol. 2012;865:115-25
references.pmid: 22528156
references.citation: Antiviral Res. 2010 Feb;85(2):381-8
references.pmid: 19917319
references.citation: Emerg Infect Dis. 2009 Apr;15(4):552-60
references.pmid: 19331731
references.citation: Influenza Other Respir Viruses. 2013 Sep;7(5):645-58
references.pmid: 23575174
references.citation: Antimicrob Agents Chemother. 2009 Nov;53(11):4845-51
references.pmid: 19687241
references.citation: Antiviral Res. 2009 Jul;83(1):90-3
references.pmid: 19501261
references.citation: J Clin Pharmacol. 2011 Feb;51(2):243-51
references.pmid: 20197485
references.citation: Clin Infect Dis. 2010 May 1;50(9):1252-5
references.pmid: 20345239